KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Equity (2017 - 2025)

Historic Return on Equity for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 0.09%.

  • Biomarin Pharmaceutical's Return on Equity rose 300.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.08% for FY2024, which is 500.0% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Return on Equity stood at 0.09% for Q3 2025, which was up 300.0% from 0.11% recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Return on Equity registered a high of 0.2% during Q2 2021, and its lowest value of 0.02% during Q4 2021.
  • In the last 5 years, Biomarin Pharmaceutical's Return on Equity had a median value of 0.03% in 2023 and averaged 0.06%.
  • Examining YoY changes over the last 5 years, Biomarin Pharmaceutical's Return on Equity showed a top increase of 1600bps in 2021 and a maximum decrease of -2300bps in 2021.
  • Biomarin Pharmaceutical's Return on Equity (Quarter) stood at 0.02% in 2021, then skyrocketed by 306bps to 0.03% in 2022, then rose by 10bps to 0.03% in 2023, then surged by 126bps to 0.08% in 2024, then increased by 12bps to 0.09% in 2025.
  • Its last three reported values are 0.09% in Q3 2025, 0.11% for Q2 2025, and 0.09% during Q1 2025.